TY  - JOUR
T1  - Role of genetic testing for screening and prevention for ovarian cancer: Comment on “risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after brca testing”
AU  - Grann V, Ashby-Thompson M
Y1  - 2013/01/28
N1  - 10.1001/jamainternmed.2013.2729
JO  - JAMA Internal Medicine
SP  - 103
EP  - 104
VL  - 173
IS  - 2
N2  - 
Genetic history of BRCA1/2 mutations identifies women who are at high risk for breast and ovarian cancer and who may benefit from more intensive screening and/or risk-reducing surgeries. BRCA1/2 mutations account for 5% to 10% of all breast cancers in the United States and approximately 10% of ovarian cancers.1 Women with mutations may develop cancers at an early age, leading to psychological distress and loss of both quality and quantity of life. The cost of preventive screening and treatment for BRCA1/2 mutations accounts for approximately $800 million of the more than $8 billion spent each year for treatment of breast and ovarian cancers.2- 3

SN  - 2168-6106
M3  - doi: 10.1001/jamainternmed.2013.2729
UR  - http://dx.doi.org/10.1001/jamainternmed.2013.2729
ER  -